Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial
Evering et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102787
https://c19early.org/evering2.html